BioCryst Pharmaceuticals, Inc.
$7.22-$0.10 (-1.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.2B
- P/E
- 8.2x
- EV / EBITDA
- 7.2x
- Revenue
- $874.8M
- Net margin
- 30.2%
- ROCE
- 107.2%
Price chart
Technical chartScreen technicals →+2.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -9.1%
- 3M
- -25.3%
- 6M
- -17.4%
- 1Y
- +2.7%
- 5Y
- -39.3%
52-week range
Day change -$0.10 (-1.4%) from $7.32 to $7.22 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BCRX, bought on each weekday since 2021.
News & filings
What BioCryst Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Revenue grew 94.1% in fiscal 2025.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Read moreShow less
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Shares outstanding
- 209.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.2B
- P/E
- 8.2x
- P/B
- -18.1x
- EV / EBITDA
- 7.2x
- EV / Sales
- 2.9x
- P/S
- 2.5x
- 52-week high
- $11.11
- 52-week low
- $6.24
Profitability
- Operating margin
- 39.0%
- Net margin
- 30.2%
- EBITDA margin
- 39.7%
- ROE
- -221.4%
- ROCE
- 107.2%
- ROIC
- 148.6%
- ROA
- 51.3%
- Asset turnover
- 1.70
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $874.8M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 94.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 47.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -396.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $344.9M
Solvency
- Current ratio
- 2.06
- Debt / Equity
- -3.68
- Debt / Assets
- 0.85
- CFO / Net profit
- 1.32
- Cash / Market cap
- 4.2%
Where the revenue went
Of every $100 of FY2025 revenue, $30 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $19.1M |
| Revenue | Gross profit | $855.8M |
| Gross profit | Operating expenses | $514.8M |
| Gross profit | Operating income | $341.0M |
| Operating income | Pretax income | $267.4M |
| Operating income | Interest and other expense | $73.6M |
| Pretax income | Tax and other | $3.5M |
| Pretax income | Net income | $263.9M |
Revenue and net profit
Revenue grew 94.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $270.8M | -$247.1M |
| FY2023 | $331.4M | -$226.5M |
| FY2024 | $450.7M | -$88.9M |
| FY2025 | $874.8M | $263.9M |
Cash flows
FY2025: $347.4M from operations, $344.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$161.8M | -$163.2M |
| FY2023 | -$95.1M | -$97.3M |
| FY2024 | -$52.0M | -$53.1M |
| FY2025 | $347.4M | $344.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $874.8M+94.1%1Y
- EBITDA
- $347.7M+2,614.3%1Y
- Net profit
- $263.9M
- Cash from operations
- $347.4M
- Free cash flow
- $344.9M
- Revenue CAGR, 3Y
- 47.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $874.8M | $347.7M | $263.9M | $344.9M | -221.4% | +94.1% | -396.9% |
Monthly returns
Month-by-month returns of BCRX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $514.2M |
| Current assets | $404.4M |
| Non-current assets | $109.8M |
| Liabilities | $633.3M |
| Current liabilities | $196.1M |
| Non-current liabilities | $437.2M |
| Equity | -$119.2M |
| Paid-in capital | $1.4B |
| Retained earnings | -$1.5B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BCRX highlighted.
P/E against peers
BCRX trades at 8.2x earnings against a peer median of -14.3x.
Not shown (no positive earnings and no EV / Sales): Mineralys Therapeutics, Inc., Enliven Therapeutics, Inc., Kodiak Sciences Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc.BCRXthis company | $2.2B | 8.2x | -18.1x | -221.4% | 7.2x |
| Immunome, Inc.IMNM | $2.2B | -10.5x | 3.5x | -33.5% | -7.1x |
| Mineralys Therapeutics, Inc.MLYS | $2.2B | -14.3x | 3.4x | -23.9% | — |
| Enliven Therapeutics, Inc.ELVN | $2.2B | -20.8x | 4.7x | -22.6% | -17.3x |
| Kodiak Sciences Inc.KOD | $2.1B | — | 13.6x | -146.1% | — |
| Aurinia Pharmaceuticals Inc.AUPH | $2.1B | 7.3x | 3.6x | 49.4% | 15.2x |
| Clover Health Investments, Corp.CLOV | $2.1B | -24.6x | 6.8x | -27.7% | — |
| NovoCure LimitedNVCR | $2.1B | — | 6.1x | -40.0% | — |
| Intellia Therapeutics, Inc.NTLA | $2.1B | — | 3.1x | -61.5% | — |
| Peer median | — | -14.3x | 4.2x | -30.6% | -7.1x |
Year-to-date ROI
BCRX since 1 January, against earlier years.
Historical volatility
BCRX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -54.8% |
| FY2023 | -31.3% |
| FY2024 | -0.6% |
| FY2025 | 39.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $874.8M |
| Cost of revenueCost Of Revenue | $19.1M |
| Gross profitGross Profit | $855.8M |
| Operating expensesOperating Expense | $514.8M |
| Research and developmentResearch And Development | $166.1M |
| Selling, general and administrativeSelling General And Administration | $348.6M |
| Total expensesTotal Expenses | $533.9M |
| Operating incomeOperating Income | $341.0M |
| Interest and other | |
| Pretax incomePretax Income | $267.4M |
| TaxTax Provision | $3.5M |
| Net incomeNet Income | $263.9M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $514.2M |
| Current assetsCurrent Assets | $404.4M |
| Non-current assetsTotal Non Current Assets | $109.8M |
| LiabilitiesTotal Liabilities Net Minority Interest | $633.3M |
| Current liabilitiesCurrent Liabilities | $196.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $437.2M |
| EquityTotal Equity Gross Minority Interest | -$119.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $347.4M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $347.4M |
| Net income, continuing operationsNet Income From Continuing Operations | $263.9M |
| Depreciation and amortisationDepreciation And Amortization | $1.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.4M |
| Depreciation | $1.4M |
| Amortization of securitiesAmortization Of Securities | -$4.3M |
| Stock-based compensationStock Based Compensation | $85.1M |
| Operating gains and lossesOperating Gains Losses | $26.4M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$4.9M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$3.6M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $17.6M |
| Asset impairmentAsset Impairment Charge | $980.0k |
| Change in working capitalChange In Working Capital | -$56.9M |
| Other non-cash itemsOther Non Cash Items | $30.9M |
| Investing cash flowInvesting Cash Flow | -$13.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$13.7M |
| Capital expenditureCapital Expenditure | -$2.5M |
| Purchase of PP&EPurchase Of PPE | -$2.5M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$2.5M |
| AcquisitionsPurchase Of Business | -$6.2M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$6.2M |
| Purchase of investmentsPurchase Of Investment | -$262.2M |
| Sale of investmentsSale Of Investment | $256.6M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$5.6M |
| Other investing changesNet Other Investing Changes | $550.0k |
| Financing cash flowFinancing Cash Flow | -$349.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$349.9M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$302.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$302.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$302.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$302.0M |
| Shares issuedIssuance Of Capital Stock | $60.0k |
| Common stock issuedCommon Stock Issuance | $60.0k |
| Net common stock issuedNet Common Stock Issuance | $60.0k |
| Stock options exercisedProceeds From Stock Option Exercised | $9.1M |
| Other financing chargesNet Other Financing Charges | -$57.1M |
| Change in cashChanges In Cash | -$16.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 127.0% |
| Cash at the start of the yearBeginning Cash Position | $106.3M |
| Cash at the end of the yearEnd Cash Position | $91.3M |
| Free cash flowFree Cash Flow | $344.9M |
| Supplemental |
Learn while you research
Academy chapters picked for BioCryst Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 8.2 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Growth Investing94% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read